Please note: In order to keep Hive up to date and provide users with the best features, we are no longer able to fully support Internet Explorer. The site is still available to you, however some sections of the site may appear broken. We would encourage you to move to a more modern browser like Firefox, Edge or Chrome in order to experience the site fully.

Supporting your high street Find out how »
FDA Review of Drug Applications, Paperback / softback Book

FDA Review of Drug Applications Paperback / softback

Edited by Morris Cooperman, Richard J Porter

Paperback / softback

Out of stock

Description

In the late 1980s, the median time for FDA to approve a new drug application (NDA) was 29 months.

Industry, consumer groups, and FDA agreed that the time from submission of a drug or biologics application to FDA's decision was unacceptably long.

Patient advocates argued that a drug in review--and therefore not available for sale -- could be the difference between life and death.

Manufacturers argued that prolonged review times affected their ability to recoup the costs of research and development.

This book examines the FDA's review of drug applications, with a focus on the Prescription Drug User Fee Act (PDUFA) and issues for reauthorization in 2012.

Information

Save 24%

£84.99

£63.99

Out of stock
Add to Basket
Sign in to add to wishlist
 
Free Home Delivery

on all orders

 
Pick up orders

from local bookshops

Information